REGENXBIO Inc. (RGNX) stock
RGNXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$7.24−0.08 (-1.09%)
Close on Nov 17, 2026Market cap $477.94MP/E –Yield –
Regenxbio cash
Cash and short-term investments held at the end of each period.
Regenxbio's cash was $105.50M at Jun 30, 2026. For fiscal 2025 it was $240.90M, down 1.6% from the year before. Over ten years it grew 1.1% a year on average. The highest annual figure on record is $849.30M in fiscal 2021.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $240.90M | -1.6% |
| FY2024 | Dec 31, 2024 | $244.90M | -22.0% |
| FY2023 | Dec 31, 2023 | $314.10M | -44.4% |
| FY2022 | Dec 31, 2022 | $565.20M | -33.5% |
| FY2021 | Dec 31, 2021 | $849.30M | +62.5% |
| FY2020 | Dec 31, 2020 | $522.50M | +30.6% |
| FY2019 | Dec 31, 2019 | $400.00M | -15.0% |
| FY2018 | Dec 31, 2018 | $470.60M | +166.8% |
| FY2017 | Dec 31, 2017 | $176.40M | +10.9% |
| FY2016 | Dec 31, 2016 | $159.00M | -26.5% |
| FY2015 | Dec 31, 2015 | $216.37M | +19201.2% |
| FY2014 | Dec 31, 2014 | $1.12M | +0.2% |
| FY2013 | Dec 31, 2013 | $1.12M | -48.3% |
| FY2012 | Dec 31, 2012 | $2.17M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $105.50M | -71.0% |
| Q1 FY2026 | Mar 31, 2026 | $150.50M | -44.8% |
| Q4 FY2025 | Dec 31, 2025 | $240.90M | -1.6% |
| Q3 FY2025 | Sep 30, 2025 | $302.00M | +8.4% |
| Q2 FY2025 | Jun 30, 2025 | $363.60M | +11.1% |
| Q1 FY2025 | Mar 31, 2025 | $272.70M | -28.3% |
| Q4 FY2024 | Dec 31, 2024 | $244.90M | -22.0% |
| Q3 FY2024 | Sep 30, 2024 | $278.60M | -23.6% |
| Q2 FY2024 | Jun 30, 2024 | $327.30M | -21.2% |
| Q1 FY2024 | Mar 31, 2024 | $380.50M | -19.6% |
| Q4 FY2023 | Dec 31, 2023 | $314.10M | -44.4% |
| Q3 FY2023 | Sep 30, 2023 | $364.50M | -40.9% |
| Q2 FY2023 | Jun 30, 2023 | $415.40M | -39.1% |
| Q1 FY2023 | Mar 31, 2023 | $473.50M | -38.1% |
| Q4 FY2022 | Dec 31, 2022 | $565.20M | -33.5% |
| Q3 FY2022 | Sep 30, 2022 | $617.00M | +15.7% |
| Q2 FY2022 | Jun 30, 2022 | $682.00M | +15.0% |
| Q1 FY2022 | Mar 31, 2022 | $764.80M | +16.5% |
| Q4 FY2021 | Dec 31, 2021 | $849.30M | +62.5% |
| Q3 FY2021 | Sep 30, 2021 | $533.50M | +84.1% |
| Q2 FY2021 | Jun 30, 2021 | $593.00M | +74.8% |
| Q1 FY2021 | Mar 31, 2021 | $656.50M | +84.1% |
| Q4 FY2020 | Dec 31, 2020 | $522.50M | +30.6% |
| Q3 FY2020 | Sep 30, 2020 | $289.80M | -30.5% |
| Q2 FY2020 | Jun 30, 2020 | $339.20M | -24.6% |
| Q1 FY2020 | Mar 31, 2020 | $356.60M | -19.7% |
| Q4 FY2019 | Dec 31, 2019 | $400.00M | -15.0% |
| Q3 FY2019 | Sep 30, 2019 | $417.10M | -12.2% |
| Q2 FY2019 | Jun 30, 2019 | $449.70M | +46.8% |
| Q1 FY2019 | Mar 31, 2019 | $444.30M | +88.4% |
| Q4 FY2018 | Dec 31, 2018 | $470.60M | +166.8% |
| Q3 FY2018 | Sep 30, 2018 | $474.90M | +148.5% |
| Q2 FY2018 | Jun 30, 2018 | $306.30M | +46.9% |
| Q1 FY2018 | Mar 31, 2018 | $235.80M | +12.5% |
| Q4 FY2017 | Dec 31, 2017 | $176.40M | +10.9% |
| Q3 FY2017 | Sep 30, 2017 | $191.10M | +3.4% |
| Q2 FY2017 | Jun 30, 2017 | $208.50M | – |
| Q1 FY2017 | Mar 31, 2017 | $209.60M | – |
| Q4 FY2016 | Dec 31, 2016 | $159.00M | – |
| Q3 FY2016 | Sep 30, 2016 | $184.86M | – |
See a number that looks wrong?